...
首页> 外文期刊>Chromatographia >Development and Validation of RP-LC Method for the Simultaneous Determination of Simvastatin and Ezetimibe in Fixed-Dose Combination Tablets and in Rabbit Serum
【24h】

Development and Validation of RP-LC Method for the Simultaneous Determination of Simvastatin and Ezetimibe in Fixed-Dose Combination Tablets and in Rabbit Serum

机译:RP-LC法同时测定辛伐他汀和依泽替米贝中的RP-LC方法及兔血清的开发与验证

获取原文
获取原文并翻译 | 示例
           

摘要

Combined drug therapy which is based on the co-administration of two or more drugs, have been used for a long time, to treat diseases. In this study, a simple, selective and rapid RP-LC method has been developed and validated for the sensitive and simultaneous determination of simvastatin (SMV) and ezetimibe (EZE) in fixed-dose combination tablets and in rabbit serum using a simple sample preparation procedure. The developed RPLC method for these lipid-lowering agents was completely validated and in the linear range of 0.05-50 mu g mL(-1) EZE and 0.05-10 mu g mL(-1) SMV. The calibration curves were obtained with limit of detection values of 0.013 mu g mL(-1), 0.009 mu g mL(-1)for EZE and SMV, respectively. The developed method was successfully applied to the analysis of EZE and SMV in fixed-dose combination tablets and in rabbit serum, and no interference was observed from any excipients and endogenous substances in the rabbit serum samples. Dissolution profiles of the pharmaceutical dosage form of these lipid-lowering agents were also studied.
机译:基于两种或更多种药物的共同施用的组合药物治疗已经使用了很长时间,以治疗疾病。在本研究中,已经开发了一种简单,选择性和快速的RP-LC方法,并验证了使用简单的样品制备的固定剂组合片和兔血清中的敏感和同时测定辛伐他汀(SMV)和ezetimibe(EZE)的敏感和同时测定程序。用于这些脂降低剂的开发的RPLC方法完全验证,在0.05-50μg(-1)喷杉的线性范围内和0.05-10μgml(-1)SMV。以EZE和SMV的0.013μg(-1),0.009μg(-1)的检测值限制,获得校准曲线。已成功应用于固定剂量组合片中的EZE和SMV的分析和兔血清的分析,并且在兔血清样品中的任何赋形剂和内源物质中没有观察干扰。还研究了这些脂质降低剂的药物剂型的溶解谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号